13F Holdings
中文EN

SLDB Solid Biosciences Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1707502 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-28.8%
TTM EPS YoY29.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-76.9%
ROA-64.9%
ROIC (approx.)-94.0%
Asset turnover—

Leverage & solvency

Liabilities / assets12.3%
Debt / equity0.00x
Current ratio11.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-4.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue———$8.09M$13.62M
R&D expense$140.32M$96.43M$76.56M$78.42M$58.74M
SG&A expense$38.88M$33.30M$27.75M$28.95M$27.14M
Operating income-$179.21M-$129.73M-$104.25M-$106.45M-$72.25M
Interest expense-$203,000$340,000$440,000——
Pretax income-$174.20M-$124.58M———
Income tax$0$0$0$0$0
Net income-$174.32M-$124.70M-$96.02M-$85.98M-$72.19M
EBITDA-$177.57M-$127.27M-$101.67M-$104.04M-$69.29M
EPS (basic)-1.99-3.06-4.83-10.10-10.14
EPS (diluted)-1.99-3.06-4.83-10.10-10.14
Weighted avg. shares (diluted)87.50M40.82M19.88M8.51M7.12M
Balance sheet
Cash & equivalents$59.90M$82.19M$75.85M$157.22M$119.14M
Short-term investments$127.95M$68.69M$49.62M$58.34M$88.64M
Current assets$205.46M$157.30M$129.73M$219.64M$222.61M
PP&E, net$4.17M$4.75M$6.62M$9.66M$6.46M
Total assets$232.54M$188.66M$164.94M$260.25M$232.38M
Current liabilities$33.47M$30.26M$14.52M$22.51M$23.60M
Total liabilities$52.53M$51.42M$38.46M$48.59M$24.17M
Shareholders' equity$180.01M$137.25M$126.48M$211.67M$208.21M
Shares outstanding78.97M40.47M20.39M19.56M7.36M
Cash flow statement
Operating cash flow-$156.29M-$100.01M-$94.18M-$97.98M-$77.76M
Capital expenditure$1.15M$654,000$1.51M$3.02M$1.28M
Free cash flow-$157.44M-$100.67M-$95.69M-$100.99M-$79.05M
Investing cash flow-$58.45M-$16.09M$9.69M$59.16M-$91.09M
Financing cash flow$194.45M$122.44M$3.12M$74.83M$134.99M
Depreciation & amortization$1.64M$2.46M$2.58M$2.41M$2.96M
Stock-based compensation$16.91M$10.52M$7.62M$7.54M$13.37M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.